Skip to main content
Clinical Trials/NCT03152006
NCT03152006UnknownNot Applicable

Adolescent Coordinated Transition (ACT) to Improve Health Outcomes Among Nigerian HIV+ Youth

University of Nevada, Las Vegas5 sites in 1 country216 target enrollmentStarted: June 28, 2017Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Enrollment
216
Locations
5
Primary Endpoint
Retention in care in care 6 months post-transfer

Study Overview

Brief Summary

The purpose of this study is to evaluate the comparative effectiveness of a comprehensive, coordinated transition protocol which includes an early introduction to the adult provider, an integrated case management team and a peer-facilitated organized support group on retention in care, viral suppression and psychosocial wellbeing among adolescents living with HIV.

Detailed Description

Using a two-arm cluster randomized design, our proposed study will evaluate the comparative effectiveness of ACT, a coordinated protocol for transitioning adolescents living with HIV (ALHIV) from pediatric to adult care (Intervention Group; IG) versus the usual abrupt transfer to adult care (Control group; CG) on rates of retention in care and viral suppression, and differences in perceived psychosocial wellbeing. Twelve health facilities, two in each of the six geopolitical zones of Nigeria will be pair-matched and randomly assigned to either IG (N=6 health facilities) or CG (N=6 health facilities). A total of 216 ALHIV will be enrolled in the study over a 36-month period. The primary outcome will be the difference in the rate of retention between the groups. Secondary outcomes will be difference in the rate of viral suppression and the difference in perceived psychosocial wellbeing. Additionally, the investigators will conduct mediation/moderation analysis to examine the role of intermediate variables such as transition readiness, perceived mental health, social support, health locus of control, self-esteem and sexual risk behavior self-efficacy on the primary outcomes. Implementation factors will be assessed using the hybrid 2 model.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Single (Participant)

Eligibility Criteria

Ages
13 Years to 17 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Documented HIV infection
  • Aware of HIV diagnosis
  • Currently on ART

Exclusion Criteria

  • Medically unstable

Arms & Interventions

Control

No Intervention

The control arm does not receive the ACT intervention.

ACT Intervention

Experimental

Intervention activities include the three components of the ACT intervention: (1) alternating pediatric and adult clinic visits in the 12 month pre-transfer period (2) peer facilitated organized support group during the 24-month graduated transition period and (3) patient advocate and case management team to coordinate transfer process.

Intervention: ACT (Other)

Outcomes

Primary Outcomes

Retention in care in care 6 months post-transfer

Time Frame: 6 months

Proportion of participants who had at least 1 clinical visit to an HIV provider within the 6 months post-transfer

Retention in care 12 months post-transfer

Time Frame: 12 months

Proportion of participants who had at least 2 clinical visits to an HIV provider separated by 6 months within the 1 year period post-transfer

Retention in care 24 months post-transfer

Time Frame: 24 months

Proportion of participants who had at least 2 clinical visits to an HIV provider separated by 6 months within a 1 year period during the second year post-transfer

Secondary Outcomes

  • Viral Suppression(Enrollment, baseline (12 months), 24 and 36 months)
  • Mental Health and Wellbeing(Enrollment, baseline (12 months), 24 and 36 months)
  • Health Locus of Control(Enrollment, baseline (12 months), 24 and 36 months)
  • Social Support(Enrollment, baseline (12 months), 24 and 36 months)
  • Sexual Risk Behavior(Enrollment, baseline (12 months), 24 and 36 months)
  • Transition Readiness(Enrollment, baseline (12 months), 24 and 36 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Echezona Ezeanolue

Professor of Public Health and Pediatrics

University of Nevada, Las Vegas

Study Sites (5)

Loading locations...

Similar Trials